Publication date: Jun 08, 2021
The drug reportedly is not for people with severe Alzeheimer’s but may be used to help offset early onset Alzeheimer’s symtoms. . Biogen’s medication is called Aducanumab and it’s for mild cognitive impairment associated with the early stages of the brain wasting disease. It will take several months for the drug to become available for most patients. Critics have expressed concerns that the drug may be too expensive. Some non-profits didn’t think the medication should be approved, though, the Alzheimer’s Association supported it. -It’s very exciting to get the FDA’s provisional approval today this is a major moment in history. We spoke with Dr. Jonathan Liss at the Columbus Memory Center about the historic day.
|disease||MESH||mild cognitive impairment|